JP2024537139A5 - - Google Patents
Info
- Publication number
- JP2024537139A5 JP2024537139A5 JP2024520707A JP2024520707A JP2024537139A5 JP 2024537139 A5 JP2024537139 A5 JP 2024537139A5 JP 2024520707 A JP2024520707 A JP 2024520707A JP 2024520707 A JP2024520707 A JP 2024520707A JP 2024537139 A5 JP2024537139 A5 JP 2024537139A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- kras
- salt
- pharmaceutically acceptable
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163252384P | 2021-10-05 | 2021-10-05 | |
| US63/252,384 | 2021-10-05 | ||
| PCT/US2022/045619 WO2023059594A1 (en) | 2021-10-05 | 2022-10-04 | Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537139A JP2024537139A (ja) | 2024-10-10 |
| JP2024537139A5 true JP2024537139A5 (https=) | 2025-09-30 |
Family
ID=85803703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024520707A Pending JP2024537139A (ja) | 2021-10-05 | 2022-10-04 | ＫＲＡＳ Ｇ１２Ｄ阻害剤とＰＩ３Ｋａ阻害剤との組み合わせ及び関連する治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240408098A1 (https=) |
| EP (1) | EP4412716A4 (https=) |
| JP (1) | JP2024537139A (https=) |
| KR (1) | KR20240073112A (https=) |
| CN (1) | CN118338904A (https=) |
| AU (1) | AU2022359282A1 (https=) |
| CA (1) | CA3233566A1 (https=) |
| IL (1) | IL311834A (https=) |
| MX (1) | MX2024004213A (https=) |
| WO (1) | WO2023059594A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| WO2025080956A1 (en) * | 2023-10-12 | 2025-04-17 | Mirati Therapeutics, Inc. | Mrtx1133 pharmaceutical compositions |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| WO2026080796A1 (en) * | 2024-10-11 | 2026-04-16 | Mirati Therapeutics, Inc. | Mrtx1133 capsule pharmaceutical compositions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| WO2014142660A1 (en) | 2013-03-12 | 2014-09-18 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combinations of inhibitors of mek, egfr and erbb2 in the treatment of kras-mutant lung cancer and kras-mutant colon cancer |
| AU2019355574A1 (en) | 2018-10-05 | 2021-05-06 | Sloan-Kettering Institute For Cancer Research | PI3K inhibitors and uses thereof |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| US20240139193A1 (en) * | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4225383A4 (en) * | 2020-10-08 | 2024-12-11 | Kumquat Biosciences Inc. | MODULATORS OF CELLULAR PROLIFERATION AND THEIR USES |
-
2022
- 2022-10-04 IL IL311834A patent/IL311834A/en unknown
- 2022-10-04 WO PCT/US2022/045619 patent/WO2023059594A1/en not_active Ceased
- 2022-10-04 JP JP2024520707A patent/JP2024537139A/ja active Pending
- 2022-10-04 CA CA3233566A patent/CA3233566A1/en active Pending
- 2022-10-04 CN CN202280077624.6A patent/CN118338904A/zh active Pending
- 2022-10-04 MX MX2024004213A patent/MX2024004213A/es unknown
- 2022-10-04 AU AU2022359282A patent/AU2022359282A1/en active Pending
- 2022-10-04 KR KR1020247014947A patent/KR20240073112A/ko active Pending
- 2022-10-04 EP EP22879172.9A patent/EP4412716A4/en active Pending
- 2022-10-04 US US18/694,848 patent/US20240408098A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024537140A5 (https=) | ||
| JP2024537139A5 (https=) | ||
| JP2022548791A5 (https=) | ||
| JP2025000632A5 (https=) | ||
| JP2024537136A5 (https=) | ||
| JP2025000629A5 (https=) | ||
| JP2024537137A5 (https=) | ||
| JP2025000630A5 (https=) | ||
| FI3849537T3 (fi) | Yhdistelmäterapioita | |
| CN105311030B (zh) | 用于抗肿瘤的螺取代化合物 | |
| JP2024540839A5 (https=) | ||
| JP2024521788A5 (https=) | ||
| JP2002532392A5 (https=) | ||
| JP2025512999A5 (https=) | ||
| Kojonazarov et al. | Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling | |
| IL311834A (en) | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods | |
| JP2023540809A5 (https=) | ||
| IL311863A (en) | Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods | |
| CN115624550A (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2016507500A5 (https=) | ||
| IL315645A (en) | Combination therapies comprising a sos1 inhibitor and an egfr inhibitor | |
| WO2007113243A2 (en) | Use of pde 5 inhibitors for the treatment of overactive bladder | |
| WO2007123511A2 (en) | Dosing regimens for the treatment of cancer | |
| JP6370801B2 (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| JP2025513802A5 (https=) |